{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:11:09Z","timestamp":1787015469721,"version":"build-2736575974"},"reference-count":59,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T00:00:00Z","timestamp":1766880000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100015661","name":"UCB Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Given the lack of head\u2010to\u2010head studies of approved biologic therapies in hidradenitis suppurativa (HS), a chronic, recurrent inflammatory skin disease, a systematic literature review (SLR) and network meta\u2010analysis (NMA) were conducted to provide insight into their comparative short\u2010term efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the relative efficacy of approved biologic therapies (bimekizumab 320\u2009mg every 2\u2009weeks [Q2W], secukinumab 300\u2009mg Q2W and every 4\u2009weeks [Q4W] and adalimumab 40\u2009mg every week [QW]) at Week 12\u201316 in moderate\u2010to\u2010severe HS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A clinical SLR identified randomised controlled trials until 3\n                      <jats:sup>rd<\/jats:sup>\n                      July 2024 for inclusion in Bayesian NMAs. Two evidence networks (predominantly biologic\u2010na\u00efve and biologic\u2010experienced) were constructed to represent populations with differing biologic treatment histories. Outcomes of interest were improved HS Clinical Response (HiSCR; \u226550%\/\u226575%\/\u226590%\/100%), change from baseline (CFB) in International Hidradenitis Suppurativa Severity Score System (IHS4) and improvement from baseline of \u226555% (IHS4\u201055). Percentage CFB in abscess and inflammatory nodule (AN) count and CFB in absolute draining tunnels (DT) count were also assessed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The NMA included nine trials. Bimekizumab ranked as the most efficacious treatment across all predefined efficacy outcomes in both predominantly biologic\u2010na\u00efve and biologic\u2010experienced networks, showing consistent response levels. In the predominantly biologic\u2010na\u00efve network, bimekizumab Q2W compared with secukinumab (Q4W) demonstrated significantly higher odds of response for all HiSCR outcomes (odds ratio [OR]: HiSCR50\u2009=\u20091.69; HiSCR75\u2009=\u20091.85; HiSCR90\u2009=\u20091.62; HiSCR100\u2009=\u20091.88) and IHS4\u201055 (OR\u2009=\u20091.91), and for HiSCR75 (OR\u2009=\u20091.60) and HiSCR90 (OR\u2009=\u20091.56) compared with adalimumab QW. Similar results were observed for secukinumab Q2W and both secukinumab dosing regimens in the biologic\u2010experienced network. Note, adalimumab studies did not report the proportion of biologic\u2010experienced patients. Systematic review of safety data is required for full benefit\u2013risk assessment and decision\u2010making.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This NMA, the first to adjust for intercurrent events in moderate\u2010to\u2010severe HS across multiple efficacy outcomes, assessed up\u2010to\u2010date data, with estimates demonstrating bimekizumab's favourable efficacy among approved biologics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.70265","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T03:35:18Z","timestamp":1766979318000},"page":"646-657","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Short\u2010term efficacy of biologics in moderate\u2010to\u2010severe hidradenitis suppurativa: A systematic review and\n                    <scp>NMA<\/scp>"],"prefix":"10.1111","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2760-3904","authenticated-orcid":false,"given":"Haley B.","family":"Naik","sequence":"first","affiliation":[{"name":"Department of Dermatology University of California  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Frank","family":"M\u00f8rup","sequence":"additional","affiliation":[{"name":"UCB  Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Davis","sequence":"additional","affiliation":[{"name":"UCB  Morrisville North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Taieb","sequence":"additional","affiliation":[{"name":"UCB  Colombes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Kiri","sequence":"additional","affiliation":[{"name":"UCB  Slough UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isobel","family":"Munro","sequence":"additional","affiliation":[{"name":"Source Health Economics  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hemstock","sequence":"additional","affiliation":[{"name":"Source Health Economics  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thrasyvoulos","family":"Tzellos","sequence":"additional","affiliation":[{"name":"European Hidradenitis Suppurativa Foundation, e.V  Dessau Germany"},{"name":"Department of Dermatology Nordland Hospital Trust  Bod\u00f8 Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Piguet","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine Women's College Hospital  Toronto Ontario Canada"},{"name":"Division of Dermatology Department of Medicine University of Toronto  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Kirby","sequence":"additional","affiliation":[{"name":"St Vincent's University Hospital, Elm Park  Republic of Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,28]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/cimb45050280"},{"key":"e_1_2_13_3_1","volume-title":"Hidradenitis Suppurativa","author":"Ballard K","year":"2024"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03356.x"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.1677"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0149-1"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16101"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00068"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1159\/000488344"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17578"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.016"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16132"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17166000"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17101"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16255"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0b013e3181ceb80c"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.12703\/P6-112"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad215"},{"key":"e_1_2_13_19_1","unstructured":"National Institute for Health and Care Excellence (NICE).Adalimumab for\u2009Treating Moderate to Severe Hidradenitis Suppurativa\u2009[ID812] Committee Papers.2016https:\/\/www.nice.org.uk\/guidance\/ta392\/documents\/committee\u2010papers"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255560"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2021.1895753"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.02.068"},{"key":"e_1_2_13_23_1","volume-title":"Dermatologic Surgery","author":"Hurley HJ","year":"1989"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17537"},{"key":"e_1_2_13_25_1","unstructured":"European Medicines Agency (EMA).Humira EPAR \u2010\u2009Product Information. Last updated 31.07.2024.2025 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/humira\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_13_26_1","unstructured":"European Medicines Agency (EMA).Bimzelx EPAR \u2010\u2009Product Information. Last updated 07.08.2024. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/bimzelx\u2010epar\u2010product\u2010information_en.pdf[Accessed February 2025]"},{"key":"e_1_2_13_27_1","unstructured":"European Medicines Agency (EMA).Cosentyx: EPAR \u2010\u2009Product Information. Last updated 07.01.20252025https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/cosentyx\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20472"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781118951651"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/096228020101000404"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1875"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.01.011"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13270"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15748"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18632"},{"key":"e_1_2_13_37_1","unstructured":"DiasS WeltonNJ SuttonAJ AdesAE.Nice DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta\u2010Analysis of Randomised Controlled Trials.2011http:\/\/www.nicedsu.org.uk\/"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200624010-00001"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.331.7521.897"},{"key":"e_1_2_13_40_1","unstructured":"Bayesian\u2009Inference\u2009Uusing Gibbs Sampling (BUGS).WinBUGS with DoodleBUGS version 1.4. Cambridge\/London UK.https:\/\/www.mrc\u2010bsu.cam.ac.uk\/bugs\/"},{"key":"e_1_2_13_41_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200826090-00006"},{"key":"e_1_2_13_42_1","unstructured":"DiasS SuttonAJ WeltonNJ AdesAE.Nise DSU technical support document 3: nice DSU technical support document 3: heterogeneity: subgroups meta\u2010regression Bias\u2009and Bias\u2010Adjustment.https:\/\/sheffield.ac.uk\/nice\u2010dsu"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0473-z"},{"key":"e_1_2_13_44_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2905"},{"key":"e_1_2_13_45_1","unstructured":"Clinicaltrials.gov.A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa (BE HEARD I).2025https:\/\/clinicaltrials.gov\/study\/NCT04242446\u2009[Accessed February 2025]."},{"key":"e_1_2_13_46_1","volume-title":"Bimekizumab in\u2009Patients With Moderate\u2010to\u2010Severe Hidradenitis Suppurativa: 48\u2010week Efficacy\u2009and Safety From Be Heard I & II, Two Phase 3, Randomized, Double\u2010Blind, Placebo Controlled","author":"Kimball AB","year":"2023"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00022-3"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-157-12-201212180-00004"},{"key":"e_1_2_13_49_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504370"},{"key":"e_1_2_13_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.040"},{"key":"e_1_2_13_51_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2021.3655"},{"key":"e_1_2_13_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21647"},{"key":"e_1_2_13_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.09.023"},{"key":"e_1_2_13_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3060"},{"key":"e_1_2_13_55_1","unstructured":"NewswirePR.UCB Receives U.S. FDA Approval for BIMZELX\u00ae (bimekizumab\u2010bkzx) as the First IL\u201017A and IL\u201017F Inhibitor for Adults with Moderate\u2010to\u2010Severe Hidradenitis Suppurativa. Press release; 20th November.2024https:\/\/www.prnewswire.com\/news\u2010releases\/ucb\u2010receives\u2010us\u2010fda\u2010approval\u2010for\u2010bimzelx\u2010bimekizumab\u2010bkzx\u2010as\u2010the\u2010first\u2010il\u201017a\u2010and\u2010il\u201017f\u2010inhibitor\u2010for\u2010adults\u2010with\u2010moderate\u2010to\u2010severe\u2010hidradenitis\u2010suppurativa\u2010302311330.html"},{"key":"e_1_2_13_56_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00540-022-03072-5"},{"key":"e_1_2_13_57_1","unstructured":"NaikHB TzellosT PiguetV DavisL M\u00f8rupMF TaiebV et\u00a0al.Bimekizumab: Matching\u2010Adjusted Indirect Comparison (MAIC) to Establish 1\u2010year Comparative Efficacy in Moderate\u2010to\u2010Severe Hidradenitis Suppurativa (HS). Poster code: CO72. 2024\u201311 ISPOR Europe 2024 Barcelona Spain. S2 (December 2024). Available from:https:\/\/www.ucbcompass.com\/sites\/default\/files\/2024\u201010\/EADV24_NMA%20Weeks%2012\u201016%20in%20HS_20Sep24Submission.pdf. Value in Health. 2024;27(12)."},{"key":"e_1_2_13_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20617"},{"key":"e_1_2_13_59_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.1976"},{"key":"e_1_2_13_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2025.2513054"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70265","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.70265","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.70265","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T14:37:13Z","timestamp":1776868633000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.70265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,28]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1111\/jdv.70265"],"URL":"https:\/\/doi.org\/10.1111\/jdv.70265","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,28]]},"assertion":[{"value":"2025-03-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}